167 related articles for article (PubMed ID: 11967386)
1. Direct versus indirect thrombin inhibition in percutaneous coronary intervention.
Marmur JD
J Invasive Cardiol; 2002 Apr; 14 Suppl B():8B-18B. PubMed ID: 11967386
[No Abstract] [Full Text] [Related]
2. Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes.
Shimpi RA
J Invasive Cardiol; 2003 Aug; 15(8):460-5. PubMed ID: 12890880
[No Abstract] [Full Text] [Related]
3. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.
Moser LR; Kalus JS
Ann Pharmacother; 2004 Dec; 38(12):2094-104. PubMed ID: 15536140
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic therapy for percutaneous coronary intervention.
Barman N; Bhatt DL
Cardiol Clin; 2006 May; 24(2):175-99, v-vi. PubMed ID: 16781937
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparins for the treatment of acute coronary syndromes.
Wong GC; Giugliano RP
Semin Vasc Med; 2003 Nov; 3(4):391-402. PubMed ID: 15199446
[TBL] [Abstract][Full Text] [Related]
6. [Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures].
Leschke M; Schoebel FC; Strauer BE
Internist (Berl); 1996 Jun; 37(6):597-606. PubMed ID: 8767992
[No Abstract] [Full Text] [Related]
7. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
Otterstad JE; Brosstad F
Scand Cardiovasc J; 2004 Mar; 38(1):9-15. PubMed ID: 15204241
[No Abstract] [Full Text] [Related]
9. Optimal antithrombotic treatment for percutaneous coronary intervention.
Kadakia RA; Ferguson JJ
Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials.
Sinno MC; Khanal S; Al-Mallah MH; Arida M; Weaver WD
Am Heart J; 2007 Apr; 153(4):579-86. PubMed ID: 17383297
[TBL] [Abstract][Full Text] [Related]
11. Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE).
Montalescot G; Van de Werf F; Gulba DC; Avezum A; Brieger D; Kennelly BM; Mazurek T; Spencer F; White K; Gore JM;
Catheter Cardiovasc Interv; 2003 Nov; 60(3):360-7. PubMed ID: 14571488
[TBL] [Abstract][Full Text] [Related]
12. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
[TBL] [Abstract][Full Text] [Related]
13. Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals.
Levine GN; Berger PB; Cohen DJ; Maree AO; Rosenfield K; Wiggins BS; Spinler SA
Pharmacotherapy; 2006 Nov; 26(11):1537-56. PubMed ID: 17064198
[TBL] [Abstract][Full Text] [Related]
14. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.
Tricoci P; Peterson ED
J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570
[TBL] [Abstract][Full Text] [Related]
15. A novel technique for coronary bifurcation lesions: cutting balloons, drug-eluting stents and the kissing technique.
Wong CB; Hardin S
J Invasive Cardiol; 2005 Feb; 17(2):108-10. PubMed ID: 15687538
[No Abstract] [Full Text] [Related]
16. Current treatment options for patients undergoing rescue coronary intervention.
Guigauri P; Dauerman HL
Minerva Cardioangiol; 2002 Apr; 50(2):85-93. PubMed ID: 12032462
[TBL] [Abstract][Full Text] [Related]
17. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive thrombolytic agents with coronary interventional techniques.
Yakubov SJ; George BS; Chapekis AT
Cardiol Clin; 1994 Nov; 12(4):573-84. PubMed ID: 7850829
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolysis and stenting in acute myocardial infarction: newlyweds destined for a 'ménage à trois'?
McFadden EP
Eur Heart J; 2001 Jul; 22(13):1067-9. PubMed ID: 11428845
[No Abstract] [Full Text] [Related]
20. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation.
Kereiakes DJ
Circulation; 2003 Oct; 108(16 Suppl 1):III22-7. PubMed ID: 14605016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
